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ABSTRACT
Combination therapy is a fast-growing strategy to maximize therapeutic benefits to patients. Co-
formulation of two or more therapeutic proteins has advantages over the administration of multiple
medications, including reduced medication errors and convenience for patients. Characterization of co-
formulated biologics can be challenging due to the high degree of similarity in the physicochemical
properties of co-formulated proteins, especially at different concentrations of individual components.
We present the results of a deamidation study of one monoclonal antibody component (mAb-B) in co-
formulated combination antibodies (referred to as COMBO) that contain various ratios of mAb-A and
mAb-B. A single deamidation site in the complementarity-determining region of mAb-B was identified
as a critical quality attribute (CQA) due to its impact on biological activity. A conventional charge-based
method of monitoring mAb-B deamidation presented specificity and robustness challenges, especially
when mAb-B was a minor component in the COMBO, making it unsuitable for lot release and stability
testing. We developed and qualified a new, quality-control-friendly, single quadrupole Dalton mass
detector (QDa)–based method to monitor site-specific deamidation. Our approach can be also used as
a multi-attribute method for monitoring other quality attributes in COMBO. This analytical paradigm is
applicable to the identification of CQAs in combination therapeutic molecules, and to the subsequent
development of a highly specific, highly sensitive, and sufficiently robust method for routine monitoring
CQAs for lot release test and during stability studies.
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Combination therapy is a fast-growing strategy used for numer-
ous drugs, including cancer immunotherapy,1-5 viral disease
treatments,6 and anti-toxins.7 For cancer immunotherapy, the
combination-based approach allows exploration of the synergis-
tic effects of two immune checkpoint inhibitors or supplementa-
tion of one immune checkpoint inhibitor with a different
treatment paradigm. Indeed, the initial clinical success of com-
bination immunotherapies8 has spurred an exponential increase
of clinical trials using this approach.5 Currently, two combina-
tional immunotherapies have been approved by the US Food
and Drug Administration for advanced melanoma and newly
diagnosed metastatic non–small-cell lung cancer.5
The subject of this study is the combination of two human
monoclonal antibodies (mAbs) (referred to herein as COMBO),
designated mAb-A and mAb-B, which, when co-formulated into
a single drug product, may have synergistic effects and additional
advantages, such as ease of use and patient safety. Compared to
marketed small molecule co-formulations, the number of peptide-
or protein-based products is very limited;9-11 only one protein co-
formulation containing rituximab (MabThera) and human hya-
luronidase is currently marketed.12 Co-formulation of therapeutic
antibodies increases the complexity of the drug product, and
hence creates challenges in characterization and release assay
development.13 This challenge is exacerbated when the co-
formulated antibodies have similar physicochemical properties
and wide disparity in their concentrations. Furthermore, each of
the co-formulated antibodies can exhibit various heterogeneities
in size, charge, and post-translational modifications (PTMs)14,15
during manufacturing.16,17
Several approaches have been widely used for the monitoring
and characterization of charge variants of recombinantmAbs. Slab
gel isoelectric focusing methods have traditionally been used for
analysis of protein charge variants,18-20 although it is more of
a qualitative than a quantitative method. Ion exchange chromato-
graphy (IEC), by the application of either a gradient of increasing
salt concentrations at a constant pH21,22 or a pH-gradient
elution,23,24 is regarded as the gold standard for the characteriza-
tion of protein charge variants, owing to its robustness and resol-
ving power,25 despite the time investment required to develop
a molecule-specific method. Capillary isoelectric focusing (cIEF)
electrophoresis with imaged technology offers reduced sample
volume, minimal development time, high resolution, and rapid
analysis.26-29 Most of the aforementioned methods have been
adopted as routine analytical tools for the analysis of charge
variants in quality control (QC) and release tests in the biophar-
maceutical industry. Nevertheless, more advanced techniques,
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such as liquid chromatography coupled with tandem mass spec-
trometry (LC-MS), provide charge variants characterization at the
peptide or residue level.30,31 Challenges remain, however, regard-
ing ways to implement these techniques into routine analysis and
regulated QC processes.32
Limited analytical methods have been reported for measuring
quality attributes in co-formulated mAbs. A size-exclusion chro-
matography (SEC) method with MS was used for analyzing
aggregates of mAb mixture.33 An enzyme-linked immunosor-
bent assay and an antibody-dependent cell-mediated cytotoxi-
city assay have been developed for a co-formulated mAbs at 1:1
ratio.6 In another study, several physicochemical methods used
in characterizing a co-formulation of 9 mAbs were reported.7
IEC showed separation of some of the mAbs and was the best
way to distinguish multiple mAbs in co-formulation compared
to SEC or gel electrophoresis methods.7 However, this study
used equal concentrations among all mAbs in COMBO; addi-
tionally, the IEC method in this study was not a quantitative
method for monitoring charge isoforms of each mAb. We were
unable to use the same approach as reported by Li et. al.7 because
we desired quantitative charge isoform distribution information
about each mAb in the COMBO, across a variety of different co-
formulation ratios.
Here, we focus on charge heterogeneity of the co-
formulated mAb-A and mAb-B in our COMBO product.
The full characterization of charge variants, critical quality
attribute (CQA) identification, and release assay development
and qualification are discussed.
Results
Development of charge variant assays for co-formulated
mAb-A and mAb-B
During individual product development of mAb-A and mAb-
B, cIEF has been used successfully to monitor charge variants
of drug substances during lot release and stability. Extensive
characterization and structure-function studies identified an
acidic charge variant of mAb-B, identified as CDR deamida-
tion, affects biologic activity. This mAb-B CDR deamidation
must also be controlled when developing COMBO, i.e., the
co-formulated mAbs. However, mAb-A and mAb-B have
similar pI values (differing by only 0.1), and it is therefore
difficult to completely resolve the charge profiles of mAb-A
and mAb-B using cIEF (as shown in Figure 1). Even as
a profile method or as a protein ratio assay, the cIEF method
is not suitable when the COMBO has different ratios of mAb-
A and mAb-B.
IEC is a popular alternative to cIEF for characterization of
charge variants. In addition to pI value, surface charge dis-
tribution also has a substantial effect on IEC retention and
separation. For example, two mAbs with identical pI values
have been reported to have large retention time differences
under IEC conditions.34 In our case, an IEC method was
developed to successfully separate mAb-A and mAb-B at
different ratios (Figure 2). The major peaks of mAb-A and
mAb-B are greater than 35 minutes apart (Figure 2(a)).
However, for stressed mAb-A and mAb-B, the IEC UV pro-
files could have coelution between some of mAb-A acidic
variants and mAb-B main peak (Figure 2(b)). Figure 3 plots
the area percent of charge variants of mAb-A and mAb-B
against its content in COMBO. For the non-stressed COMBO
drug product, quantitation of mAb-A and mAb-B charge
variants were comparable across most of the mAb-A: mAb-
B ratios (Figure 3(a,b)). However, robustness became
a concern when the percentage of one of the mAbs in the
COMBO was too low (such as at mAb-A:mAb-B ratios of
1:20, 20:1 and 30:1) because the UV signals were too low to
accurately integrate for the acid or basic variants of the minor
component. For the COMBO stressed at 40ºC for 3 months,
the quantitation of mAb-A charge variants is similar in dif-
ferent ratios in COMBO except when mAb-A:mAb-B is 1:30
(Figure 3(c)). On the other hand, the quantitation of mAb-B
charge variants in stressed COMBO by IEC is more difficult.
For, example, when mAb-B is less than 50% in the COMBO,
the area percent of basic peaks of mAb-B are greatly inflated,
Figure 1. cIEF electropherograms of COMBO with various mAb-A: mAb-B ratios.
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whereas the area percent of main and acidic peaks are under-
estimated correspondingly (Figure 3(d)).
Characterization of IEC charge variants in stressed COMBO
indicated that mAb-A acidic variants formed under stressed con-
ditions co-eluted withmAb-B charge variants in IEC. ThesemAb-
A acidic variants have been identified by LC-MS as small hinge
fragments (SHF) and large hinge fragments (LHF). SEC fractions
of these hinge fragments have been collected from 40°C stressed
mAb-A and injected to IEC column. Itwas confirmed that they co-
elutewithmAb-Bunder the same IEC condition (Figure 4). Figure
4 is an IECUVoverlay of three samples: the non-stressedCOMBO
containing 5% mAb-B and 95% mAb-A (in blue trace), the
enriched mAb-A LHF from SEC fraction of 40°C 3-month
stressed mAb-A (in red trace), and the enriched mAb-A SHF
from SEC fraction of 40°C 3-month stressed mAb-A (in green
trace). The results demonstrated that both LHF and SHF from
Figure 2. IEC charge variant profiles of non-stressed and stressed COMBO with various mAb-A: mAb-B ratios. The main peak split in mAb-B is caused by IgG2
disulfide bond isoforms (mainly B and A/B forms). (a) non-stressed COMBO; (b) COMBO stressed at 40°C for 3 months.
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mAb-A co-elutedwithmAb-B inCOMBO, interferingwithmAb-
B charge variants quantitation. Additional efforts to separate these
mAb-A fragments from mAb-B using IEC chromatography were
unsuccessful. As a result, the percentage of mAb-B charge variants
cannot be accurately quantified under stressed conditions, espe-
ciallywhenmAb-A is the dominant constituent in co-formulation.
Characterization of charge variants and identifying CQA in
COMBO by IEC
To further characterize the charge variants in COMBO and
the limitation of the IEC method, IEC fractionation was
performed on the non-stressed COMBO drug product with
mAb-B as a minor component. The fractions were analyzed
by intact mass analysis using RP-LC/MS for peak identifica-
tion, peptide mapping with MS/MS for post-translational
modification quantitation, and bioassay for biological activity.
The same experiment was performed on stressed COMBO at
the same ratio. All the charge variants in COMBO matched
what had been identified in individually formulated mAb-A
and mAb-B under both recommended storage and stress
conditions as shown in supplementary material (the IEC
peak fractions are labeled in Figure S1, and the identification
Figure 3. IEC quantitation of charge variants of mAb-A and mAb-B in non-stressed COMBO and stressed COMBO with various mAb-A:mAb-B ratios. (a) and (b) non-
stressed COMBO; (c) and (d) COMBO stressed at 40°C for 3 months.
Figure 4. IEC UV overlays of non-stressed COMBO drug product containing 5% mAb-B and 95% mAb-A (in blue trace), mAb-A large hinge fragment (LHF) from SEC
fraction of 40°C stressed mAb-A (in red trace), and mAb-A small hinge fragment (SHF) from SEC fraction of 40°C stressed mAb-A (in green trace).
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and biological activity impact assessment are reported in
Tables S1 and S2.). No new charge variants were generated
due to the co-formulation of mAb-A and mAb-B. Among all
the charge variants, only the CDR deamidation from mAb-B
in the COMBO had an impact on biological activity and was
therefore identified as a CQA for COMBO that requires
monitoring. All other charge variants in the COMBO were
non-CQAs. This observation was consistent with CQA deter-
minations for charge variants in individual mAb-A and
mAb-B.
It is not uncommon to have very different concentrations
of co-formulated antibodies.35 In practice, a method that is
able to cover co-formulations with wider concentration dis-
parity is always preferred to allow clinical flexibility. Even
with non-stressed COMBO drug product where the interfer-
ence from mAb-A fragments are minimal, the robustness of
quantitating the charge variants at low levels from the minor
species becomes greatly compromised when minor species
content drops to less than 5% in COMBO. This challenge
arises from the dynamic range of UV-based quantification,
and is not specific to our COMBO.
In summary, the IEC method lacked the specificity and
robustness required for quantitative measurement of mAb-B
charge variants as routine lot release and stability testing for
COMBO. It could, however, be utilized for product character-
ization to qualitatively evaluate the overall charge variants
profiles of COMBO.
Evaluation of peptide mapping for monitoring critical
charge variants in COMBO using MS or UV signal
Tryptic peptide mapping with MS was evaluated for monitor-
ing critical charge variant of mAb-B at various mAb-A:mAb-B
ratios. Comparable quantitation results were obtained for
mAb-B CDR deamidation in different ratio of mAb-A to
mAb-B (Figure 5). The non-stressed COMBO drug product
(stored at 2–8°C), as well as the stressed COMBO samples
(stressed at 40°C for 3 months), produced comparable results
across all mAb-A: mAb-B ratios, demonstrating that peptide
mapping is an appropriate method to quantitatively monitor
mAb-B CDR deamidation in combo products. Moreover, pep-
tide mapping with ion trap MS-based detection and quantita-
tion can provide high-sensitivity and site-specific information
on charge variants, which are lacking in other charge-based
assays. However, utilizing peptide mapping with ion trap MS-
based detection and quantitation in QC laboratories is accom-
panied by its own challenges, as it requires a high-end mass
spectrometer and complex instrument operation, data proces-
sing, and instrument and method validation.
We evaluated a UV chromatogram from a tryptic digest of
the COMBO and found it to be unsuitable for monitoring mAb-
B CDR deamidation, especially if mAb-B is a minor component
(Figure 6). Insufficient resolution of the UV-basedmethodmade
it difficult to separate and quantify the CDR deamidation–
related peptides (L3 and L3L4) from other peptides in the
COMBO. When the percentage of mAb-B was <10%, peptides
from mAb-B were not detectable and the UV profile of the
COMBO appeared identical to that of mAb-A (Figure 6(c,d)).
Development of a quadrupole dalton-based focused
peptide mapping method to quantitate mAb-B CDR
deamidation as a lot release and stability assay
To quantitatively monitor the CDR deamidation of mAb-B in
the COMBO for lot release and stability, we developed and
implemented a focused peptide mapping method using
a quadrupole Dalton (QDa) mass detector. We evaluated its
specificity, sensitivity, resolution, and simplicity in transfer-
ring to the QC laboratory. The method development involved
optimizing the sample preparation; selecting a mass charge
ratio for selected ion recording (SIR) channels; optimizing
cone voltages, capillary voltages, and probe temperatures for
ion intensity; evaluating trifluoroacetic acid (TFA) versus
formic acid as an ion-pairing reagent in the mobile phases
for reduced peak interference; and verifying quantitation
results by comparison with conventional peptide mapping
data using an ion trap mass detector.
Optimizing the sample preparation for enzyme digestion
The denaturing buffer consisted of 1.3 M guanidine hydro-
chloride, 8 M urea, and 100 mM tris(hydroxymethyl)amino-
methane (Tris), which circumvented the buffer exchange–
desalting step that is typically used in conventional peptide
mapping protocols in which a high concentration of guani-
dine hydrochloride is used. The benefits of skipping the buffer
exchange step include simplicity of sample handling, shorter
sample preparation time, consistent peak intensities, and fea-
sibility of adaptation for future automation. The digestion
conditions were also optimized by adjusting the buffer pH,
trypsin: protein ratio, and digestion time to minimize sample
preparation-induced deamidation and to maximize complete
digestion. Three digestion conditions, designated A, B, and C,
were explored (Table S3 and Figure S2). Digestion condition
C was selected for the COMBO due to its relatively low levels
of assay artifacts on deamidation and its high rate of
Figure 5. mAb-B CDR deamidation measured by peptide mapping using an ion
trap mass detector in non-stressed and stressed COMBO antibody with various
mAb-A: mAb-B ratio. A: mAb-A; B: mAb-B.
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completion of digestion. The other two digestion conditions
had either high levels of deamidation artifacts (condition A)
or incomplete digestion peak at 78 min (condition B).
QDa-based focused peptide mapping method for
quantification of mAb-B CDR deamidation in COMBO
Details of the QDa-based focused peptide mapping method
are described in the Materials and Methods section. To
quantify mAb-B CDR deamidation in COMBO, six tryptic
peptides containing the CDR deamidation site in mAb-B
were monitored: two native peptides, L3 and L3L4, and two
isomeric deamidated peptides from each native peptide. The
mass charge ratios of these peptides were selected and
utilized in the SIR channels for specific functions of the
QDa method. Ions with these mass charge ratios were
detected and quantitated by the QDa mass detector in
specified retention time windows. For maximum sensitivity,
the highest-intensity monoisotopic masses of each peptide
were selected in the SIR channel. A range of cone voltages,
capillary voltages, and probe temperatures were screened in
multiple injections to achieve optimal peak intensities. SIR
profiles in which either TFA or formic acid was used as an
ion-pairing reagent in mobile phases were compared, and
TFA was selected due to its lower peak interference from
the sample matrix.
Figure 7 shows example QDa profiles from the non-
stressed COMBO drug product and COMBO drug product
stressed at 25ºC for 6 months, both containing a mAb-B as
a minor component (5%). Figure 7(a) shows where the SIR
channels for L3 and deamidated L3 were monitored. It is
possible some interfering peaks with similar m/z monitored
by the SIR channel may appear, as the resolution of the QDa
mass detector is only 0.7 Dalton. An example of an interfering
peak is the 32.8 min peak in SIR channels for quantitating L3
and deamidated L3 in Figure 7(a). To ensure correct peak
assignment, all peaks monitored by QDa were confirmed by
a high-resolution mass spectrometer that provided both mass
spectrometry and tandem mass spectrometry information
during method development. Also, the interfering peaks
tend to have constant peak intensities in all samples, regard-
less of stress conditions, as seen for peaks at 32.8 min in
Figure 7(a).
In addition to peak identification, the levels of CDR dea-
midation measured by the QDa method were verified by
conventional peptide mapping using extracted ion chromato-
gram (XIC) quantitation. COMBO drug product containing
mAb-B as a minor component was stressed in two different
buffers having the same components, but differentiated by pH
(pH 6.0 and 6.5). Under each pH condition, samples were
kept for up to 6 months at 2–8°C and 25°C, and up to
3 months at 40°C. Data obtained from the QDa-based method
Figure 6. UV (220 nm) chromatograms of tryptic digest of mAb-A, mAb-B and COMBO antibodies containing mAb-A: mAb-B at 1:1 and 10:1. (a) mAb-B; (b) COMBO
containing mAb-A: mAb-B at 1:1; (c) COMBO containing mAb-A: mAb-B at 10:1; (d) mAb-A.
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were comparable to those from the conventional peptide
mapping method using an ion-trap mass spectrometer
(Figure 8).
In another experiment, CDR deamidation data from
a COMBO with mAb-B as a minor component was com-
pared with deamidation data from an individual mAb-B
drug substance under the same heat stress conditions (tem-
perature 5 to 40°C, pH 5.5 to 6.5, incubation time
3 months). Comparable results were obtained for both the
COMBO and the stand-alone mAb-B (Figure 9). These
results indicate that mAb-B CDR deamidations were inde-
pendent of the co-formulated mAb-A. Interaction between
these two antibodies, which could affect the critical charge
variants or its degradation rate in the COMBO, was not
observed.
In addition to its application in monitoring mAb-B CDR
deamidation (a CQA) in COMBO, the QDa-based method
was also developed as a multi-attribute method for COMBO
by including ions representing other quality attributes, such as
Fc Asn deamidation, and CDR Trp oxidation, of mAb-B in
COMBO in the SIR channels for monitoring. Results from the
QDa-based method were comparable to those of conventional
peptide mapping using ion trap XIC quantitation in monitor-
ing multiple quality attributes. The data are shown in
Figure S3.
Qualification of the QDa-based focused peptide mapping
method for monitoring mAb-B CDR deamidation in
COMBO
After establishing the QDa-based focused peptide mapping
method for monitoring mAb-B CDR deamidation in COMBO,
we undertook efforts to qualify the method to support its use as
a lot release and stability-indicating assay in a goodmanufacturing
practice (GMP) environment. To this end, we evaluated several
key characteristics of the assay according to the validation design
described in the International Conference on Harmonization
(ICH) guideline Q2(R1).36 The ability of this method to quantify
CDR deamidation from minor components of COMBO was
evaluated by determining the assay’s specificity, linearity, accuracy,
precision, and limit of quantitation (LOQ) and limit of detection
(LOD). Both the stressed and the non-stressed combo drug pro-
duct containing mAb-B as a minor component were used for
method qualification. The qualification results are summarized
in Table 1, and details are discussed in supplementary material.
Discussion
Charge variants and impurities can have an impact on the
performance of co-formulated combination antibodies, hence
they need to be characterized and monitored appropriately,
Figure 7. CDR deamidation related-peaks in non-stressed COMBO drug product stored at 2–8°C and 25°C 6-month stressed COMBO antibodies, both containing
mAb-B as minor species (5%). (a) L3 and L3(D) in non-stressed COMBO drug product; (b) L3 and L3(D) in 25°C 6-month stressed COMBO ; (c) L3L4 and L3L4(D) in non-
stressed COMBO drug product; (b) L3L4 and L3L4(D) in 25°C 6-month stressed COMBO. DP: drug product.
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which may require multiple analytical methods. In this study,
the charge variants of individual mAbs in COMBO were
characterized and a CQA, a CDR deamidation from one anti-
body component, was identified. Methods such as cIEF are
not applicable for monitoring charge variants in COMBO
product when the pI of individual mAb are very close and
there is a wide disparity in their concentrations. An IEC
method is used as a characterization and comparability test
for qualitative measurement of overall profiling of charge
variants, but not for site-specific CQA monitoring. A high-
sensitivity, QDa-based, focused peptide map method is devel-
oped to quantify the CDR deamidation. This method can
quantify CDR deamidation from one component in
COMBO in a wide ratio range, even if it is from the very
minor component of the COMBO. The QDa-based method
had a sensitivity comparable to that of the ion-trap peptide
mapping method used in development laboratories, but
because its mass detector and software are designed for
a QC environment, this method was successfully qualified
and transferred to a GMP environment and validated as
a lot release and stability testing assay. The new method
demonstrated good specificity and accuracy, a low LOQ, and
good dynamic range for quantitation of a CQA in combina-
tion therapeutic molecules.
Materials and methods
Chemicals, recombinant proteins, and combination
proteins
mAb-A and mAb-B were full-length human IgG1 and IgG2
antibodies produced in Chinese hamster ovary cells and NS0
cells, respectively, by MedImmune (Gaithersburg, MD).
Trypsin was obtained from Promega (Madison, WI).
Dithiothreitol (no-weight format) was obtained from Pierce
Protein Biology (Rockford, IL). Urea (OmniPur), water
(OmniSolve, HPLC and spectrophotometry grade) and acet-
onitrile (OmniSolve, HPLC and spectrophotometry grade)
were obtained from EMD (Billerica, MA). Iodoacetamide
(OneQuant) was obtained from G-Biosciences (St. Louis,
MO). TFA in flame-sealed, 1-mL ampules was obtained
from Sigma-Aldrich (St. Louis, MO). COMBO was made by
mixing mAb-A and mAb-B at protein concentration ratios of
30:1, 20:1, 10:1, 1:1, 1:10, 1:20, and 1:30.
IEC for charge profiling
IEC was used to measure the charge heterogeneity of mAb-
A and mAb-B and to collect each individual peak for
characterization and identification. Analysis and peak col-
lection were performed on a 1100/1200 liquid chromato-
graphy system with a binary or quaternary pump (Agilent,
Santa Clara, CA). mAb-A and mAb-B were injected onto
an analytical ProPac WCX-10 column (4 mm × 250 mm;
Thermo Fisher Scientific, Waltham, MA) connected to
a ProPac WCX-10G guard column (4 mm × 50 mm;
Thermo Fisher) at a column temperature of 25°C. mAb-A
Figure 8. Comparison of CDR deamidation by the QDa-based method and
peptide mapping using heat-stressed COMBO antibody over a pH range of
6.0–6.5. (A) pH 6.0; (B) pH 6.5.
Figure 9. Comparison of CDR deamidation in COMBO and individual mAb-B
under heat stress conditions over a pH range of 5.5–6.5 (COMBO containing
mAb-B as a minor component).
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and mAb-B were eluted in a salt gradient from 30–100%
(solvent B) over 80 min with mobile phase A composed of
20 mM sodium phosphate, pH 6.0, and mobile phase
B composed of 20 mM sodium phosphate and 100 mM
sodium chloride, pH 6.0, at a flow rate of 1.0 mL/min. The
eluted protein was detected by UV absorbance at 220 nm
with a diode array detector to assess charge heterogeneity.
Results are reported as percentage of acidic peaks (pre-
peaks), percentage of main peak, and percentage of basic
peaks (post-peaks) of mAb-A and mAb-B. For character-
ization and peak identification, each individual peak was
collected by connecting a fraction collector (Agilent) to the
liquid chromatography system. All of the fractions collected
for each individual peak were pooled, buffer exchanged to
remove residual salt, and concentrated.
cIEF for charge profiling
Each sample was diluted to 0.3 mg/mL in a master mix
containing 0.35% methylcellulose solution; 4% Pharmalyte,
pH 3–10; 0.005% pI marker 5.85, and 0.005% pI marker
9.46. The samples were then loaded onto an iCE280 analyzer
(Protein Simple, San Jose, CA) and focused at 1,500 V for
1 min, followed by 3,000 V for 5 min. The protein was
detected under UV at 280 nm. The resulting electrophoresis
profiles were analyzed with the use of Empower software
(Waters, Milford, MA).
Tryptic peptide mapping with mass spectrometry for
post-translational modifications
Peptide mapping was used to verify primary sequences and
evaluate posttranslational modifications. Samples were diluted
to 10 mg/mL; mixed with a denaturing buffer composed of
1.3 M guanidine, 8 M urea, 130 mM Tris at pH 8.0, and
500 mM dithiothreitol; vortexed; and incubated at 37°C for
30 min. Iodoacetamide was added for alkylation, and the
mixture was incubated in the dark at room temperature for
30 min. The reduced and alkylated samples were diluted in
100 mM Tris buffer (pH 7.5) and then digested with trypsin at
37°C for 3 h. The digestion was quenched with TFA before
LC/MS analysis.
Focused peptide mapping for quantitation of CDR Asn
deamidation
Focused peptide mapping was used to quantitate site-specific
posttranslational modifications of proteins. The trypsin diges-
tion procedure was the same as described above for the regular
peptide mapping method. The digested peptides were separated
with a reversed-phase C-18 column, using an Acquity ultra-
performance liquid chromatography (UPLC) system (Waters),
and detected by UV and a QDa mass detector. Modified pep-
tides were resolved from native peptides by their differences in
masses and retention times. Identification of both native and
modified peptides was further confirmed by an injection of
synthetic peptide standards. Quantitative results were obtained
by using peak areas defined by the modified and unmodified
peptides and are reported as percentage of modification.
Abbreviations
CDR complementarity-determining region
cIEF Capillary isoelectric focusing
CQA critical quality attribute
CV coefficient of variation
Fc crystalizable fragment
GMP good manufacturing practice
LC-MS liquid chromatography with mass spectrometry
LHF large hinge fragments
LOD limit of detection






SHF small hinge fragment
SIR selected ion recording
TFA trifluoroacetic acid
Table 1. Summary of qualification results.
Non-stressed Stressed
Specificity Mean %CDR deamidation % CV Mean %CDR deamidation % CV
Precision-repeatability (6 preps × 1 injection) 6.5 2.5 58.5 0.5
Intermediate precision
3 preps/day, 2 days
6.5 2.5 58.4 0.5
3 preps/analyst, 2 analysts 6.4 2.6 58.5 0.6
6 preps/lab, 2 labs 6.6 4.5 58.0 1.2
Linearity and range 0.9982 r2 with a range of 6 spiking levels
σ 0.89294
S 1.96387
LOQ, %CDR deamidation, from calibration curve, 10 (σ/S) 1.5
LOD, %CDR deamidation, from calibration curve, 3.3 (σ/S) 4.5
Accuracy at % spiking levelb % Recovery % CV
10% (low) 106 1.4
55% (middle) 97 0.4
85% (high) 99 0.3
aThere was no response for the buffer blank and a positive response for the known sample.
bAccuracy was determined at three levels with three replicates each.
σ = standard deviation of the regression line (in this study, the standard deviation of y-intercepts of the regression lines); CV = coefficient of variation; LOD = limit of
detection; LOQ = limit of quantitation; S = slope of the regression line.
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XIC extracted ion chromatogram.
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